Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 8Expanded_access 1

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Neoplasms by Site 1Neoplasms 1Breast Neoplasms 1Breast Diseases 1Brain Neoplasms 1

Interventions

3-Iodobenzylguanidine 9TIC10 compound 3vorasidenib 1ulixertinib 1tucatinib 1tovorafenib 1rindopepimut 1pembrolizumab 1pegfilgrastim 1paclitaxel-Angiopep-2 conjugate 1omburtamab I-131 1mogamulizumab 1mirdametinib 1gallium maltolate 1fluorodopa F 18 1efineptakin alfa 1carbon-11 methionine 1avapritinib 1Vorinostat 1Vaccination 1Proton Pump Inhibitors 1Potassium Iodide 1OKN 007 1Methionine 1Ketoconazole 1Ipilimumab 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Fenretinide 1Eflornithine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × tucatinib × CNS × Clear all
NCT03424473 2020-02-25

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Seagen Inc.

No longer available
BreastCNS

Brain Neoplasms, Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡